These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 28360208

  • 1. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.
    Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL.
    J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
    [Abstract] [Full Text] [Related]

  • 2. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 3. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K, Le Goupil D, Quere G, Delcroix O, Gouva S, Schick U, Salaun PY, Abgral R, Alavi Z, Keromnes N, Querellou S.
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.
    Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA.
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [Abstract] [Full Text] [Related]

  • 5. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
    Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
    [Abstract] [Full Text] [Related]

  • 6. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
    Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
    Annovazzi A, Vari S, Giannarelli D, Pasqualoni R, Sciuto R, Carpano S, Cognetti F, Ferraresi V.
    Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
    [Abstract] [Full Text] [Related]

  • 8. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ.
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [Abstract] [Full Text] [Related]

  • 9. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 10. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 18; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 11. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
    Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2021 Jun 18; 48(6):1932-1943. PubMed ID: 33336264
    [Abstract] [Full Text] [Related]

  • 12. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 18; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 13. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.
    J Nucl Med; 2019 Mar 18; 60(3):328-334. PubMed ID: 30030343
    [Abstract] [Full Text] [Related]

  • 14. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 18; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

  • 15. Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor.
    Gideonse BM, Birkeland M, Vilstrup MH, Grupe P, Naghavi-Behzad M, Ruhlmann CH, Gerke O, Hildebrandt MG.
    Jpn J Radiol; 2024 Jul 18; 42(7):753-764. PubMed ID: 38504000
    [Abstract] [Full Text] [Related]

  • 16. The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.
    Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2023 Jul 18; 50(9):2699-2714. PubMed ID: 37099131
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC.
    Eur J Nucl Med Mol Imaging; 2015 Mar 18; 42(3):386-96. PubMed ID: 25359635
    [Abstract] [Full Text] [Related]

  • 18. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PET.
    Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M.
    Theranostics; 2020 Mar 18; 10(2):925-937. PubMed ID: 31903160
    [Abstract] [Full Text] [Related]

  • 19. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing 18F-FDG PET/CT with Conventional CT.
    Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG.
    J Nucl Med; 2023 Mar 18; 64(3):355-361. PubMed ID: 36207136
    [Abstract] [Full Text] [Related]

  • 20. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A.
    Radiology; 2016 Jul 18; 280(1):220-9. PubMed ID: 26854705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.